Recent developments include insider share sales and multiple deadline extensions to complete the initial business combination, with associated extension payments and promissory notes issued.

• An insider holding 10% of shares sold 150,000 shares in February 2025 [N1].
• The company has extended the deadline to consummate its initial business combination multiple times, with the latest extension to July 6, 2026, supported by extension payments deposited into the trust account [S1][S2].
• In connection with the extensions, the company has issued unsecured promissory notes to cover extension fees [S2].

The company’s management team has relevant experience in healthcare and finance, which may support effective identification and integration of a business combination target. The company has raised significant capital through its IPO and maintains funds in trust to support a business combination. The multiple deadline extensions indicate ongoing efforts to complete a transaction. Insider share sales have been disclosed transparently.

The company has not commenced operations or generated revenue, limiting visibility into its business model execution. It has a working capital deficit and material weaknesses in internal controls, which may pose operational risks. The repeated extensions to complete a business combination suggest challenges in identifying or closing a suitable target. The company’s liquidity position is constrained, and there is uncertainty about the timing and success of a business combination.

As a SPAC, Aimei Health Technology's moat is primarily its access to capital raised through its IPO and its management team's experience in healthcare and finance. The company’s ability to identify and complete a business combination with a suitable healthcare innovation target is central to its value proposition. However, as it has not commenced operations or generated revenue, its competitive advantages depend on successful execution of its business combination strategy and post-combination operational performance.

• Business Combination Risk: The company must complete a business combination by the extended deadline or cease operations and liquidate, raising substantial doubt about its ability to continue as a going concern.
• Liquidity Risk: The company has a working capital deficit and limited current assets relative to current liabilities, which may constrain its ability to fund operations and complete a business combination.
• Internal Control Weaknesses: Material weaknesses in internal controls related to segregation of duties and limited personnel have been identified, which could affect financial reporting and operational effectiveness.
• Operational Inactivity: The company has not generated operating revenue and has limited operational history, increasing uncertainty about future performance post-business combination.